As President Trump guts American research institutions, world leaders see a “once-in-a-century brain gain opportunity.”
Category: Research
-
Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.
-
A Decade-Long Search for a Battery That Can End the Gasoline Era
Can a small Massachusetts start-up perfect a battery that would make electric vehicles cheaper and more convenient than conventional cars?
-
Ronan the Sea Lion Is Probably Better Than You at Keeping a Beat
As she has aged, the pinniped’s rhythmic abilities have only improved.
-
Young People Are Not As Happy As They Used to Be, Study Finds
New data collected from more than 200,000 people across the world shows that young people aren’t as happy as they used to be.
-
Trump’s Cuts to Science Funding Could Hurt U.S. Economy, Study Shows
Reducing federal support for research and development could cause long-run economic damage and reduce government revenue.
-
F.D.A. Scientists Are Reinstated at Agency Food Safety Labs
After 20 percent of the agency’s work force was cut, federal health officials have decided to bring back some experts and review firings to fill gaps in critical roles.
-
New Study Could Bolster Climate Laws to Make Polluters Pay
Vermont was the first state to try to hold polluters accountable for climate disasters. New research aims to assign specific responsibility.
-
Daily Pill May Work as Well as Ozempic for Weight Loss and Blood Sugar
Clinical results of a GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable drugs.
-
A Scientist Is Paid to Study Maple Syrup. He’s Also Paid to Promote It.
Funded by the maple industry, a researcher has exaggerated his findings to suggest that syrup could help prevent serious diseases.
-
FDA Layoffs Could Raise Drug Costs and Erode Food Safety
Trump cutbacks were supposedly aimed at administrators. But scientists in food and drug-testing labs and policy experts who advance generic drug approvals were also dismissed.